Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis

Supplementary Appendix

Authors: Eric A. Coomes, M.D.; Hourmazd Haghbayan, M.D., M.Sc., FRCPC

SUPPLEMENTARY APPENDIX

Table of Contents

S1. Search Strategy

S2. Cytokine and Inflammatory Markers, other than IL-6

S3. Risk of Bias Assessment via the Quality in Prognostic Studies (QUIPS) Tool of Included Cohort Studies Relating IL-6 Levels with Disease Severity

S4. Supplemental References

S1. Search Strategy

Ovid MEDLINE and EMBASE

1. (severe acute respiratory syndrome OR SARS OR SARS-CoV OR SARS CoV OR novel coronavirus OR nCoV OR 2019-nCoV OR COVID OR SARS-CoV-2 OR COVID-19 OR Wuhan).ti,ab,kf,kw. OR exp severe acute respiratory syndrome coronavirus 2/

2. (tocilizumab OR toculizumab OR atlizumab OR actemra OR siltuximab OR sarilumab OR kevzara).ti,ab,kf,kw. OR exp tocilizumab/ OR exp siltuximab/ OR exp sarilumab/

3. (IL-6 OR cytokine OR interleukin OR macrophage activation syndrome OR hemophagocytic lymphohistiocytosis OR HLH).ti,ab,kf,kw. OR exp Cytokines/ OR exp cytokine/ OR exp Interleukins/ OR exp Interleukin-6/ OR exp interleukin 6/ OR exp Receptors, Interleukin-6/ OR exp Macrophage Activation Syndrome/ OR exp Lymphohistiocytosis, Hemophagocytic/ OR exp hemophagocytic syndrome/

4. #1 AND (#2 OR #3)

5. limit 5 to yr="2019 -Current"

Ovid MEDLINE and EMBASE

1. (novel coronavirus OR nCoV OR 2019-nCoV OR COVID OR SARS-CoV-2 OR COVID-19 OR Wuhan).ti,ab,kf,kw. OR exp severe acute respiratory syndrome coronavirus 2/

2. limit 5 to yr="2020 -Current"

MedRXiv, BioRXiv, ChinaRXiv:

"tocilizumab" w/ date limit 2019/01/01 - 2020/03/15

Google Scholar:

("severe acute respiratory syndrome" OR "SARS" or "SARS-CoV" or "SARS CoV" or "nCoV" or "2019-nCoV" or "COVID" or "SARS-CoV-2" or "COVID-19") AND ("tocilizumab") w/ date limit 2019/01/01 - 2020/03/15

S2. Cytokine and Inflammatory Markers, other than IL-6

Beyond IL-6, several other cytokines, inflammatory markers, and acute phase reactants were associated with disease severity and clinical outcomes. In a landmark early cohort on COVID-19 in Wuhan, Huang et al.,1 cytokine levels were higher amongst COVID-19 patients requiring ICU care compared to healthy controls for IL-6 (median 6.1 pg/mL, IQR 1.8-37.7 versus 0 pg/mL, IQR 0-0; p=0.003). IL-2 levels were significantly higher in patients requiring ICU compared to those not requiring ICU admission (median 8.6 pg/mL, IQR 7.6-12.7 versus median 6.3 pg/mL, IQR 4.3-9.9; p=0.043)


Diao et al.2 identified elevated IL-6, TNF- α , and IL-10 levels across patients with COVID-19, with significantly higher levels amongst patients required ICU admission.

Chen et al.3 identified a gradient of IL-6 and IL-2 receptor (IL-2R) levels elevations with increasing severity of COVID-19 disease; levels of both significantly increased from mild disease (soluble IL-2R: 631 ± 37 U/mL; IL-6: 34 ± 7 pg/mL), to severe disease (sIL-2R: 902 ± 51 U/mL; IL-6: 52 ± 11 pg/mL), to critically ill (sIL-2R: 1185 ± 80 U/mL; IL-6: 108 ± 12 pg/mL). In contrast, levels of IL-1 β , IL-8, IL-10, and TNF- α were not significantly different across the spectrum of disease severity.

Qin et al.4 similarly identified that severe cases have significantly elevated levels of serum inflammatory biomarkers compared with non-severe cases, including IL-6 (25.2 pg/mL versus 13.3 pg/mL; p<0.001), IL-2R (757 U/mL versus 663.5 U/mL; p=0.001), and ferritin (800.4 mcg/L versus 523.7 mcg/L; p<0.001). Additional elevations were identified amongst severe cases for TNF- α (8.7 pg/mL versus 8.4 pg/mL; p=0.037), IL-10 (6.6 pg/mL versus 5.0 pg/mL; p<0.001), and CRP (57.9 mg/L versus 33.2 mg/L; p<0.001).

Liu et al.5 identified significantly increased levels of IL-6 amongst severe cases (median 36.5, IQR 30.8-42 versus median 2.4, IQR 2.1-2.9; p=0.016). Patients with severe disease also had elevations of ferritin, ESR, and CRP. Baseline levels of IL-2, IL-4, IL-10, TNF- α , and IFN- γ were within the normal range.

In the analysis of risk factors for ARDS and death by Wu et al.,⁶ patients with COVID-19 who progressed to ARDS had significantly increased IL-6 (median 7.39 pg/mL, IQR 5.63-10.89 versus median 6.29 pg/mL, IQR 5.36-7.83; p=0.03) and ferritin (median 1029.28 mcg/L, IQR 546.26->2000 versus median 457.66 mcg/L, IQR 223.73-702.65; p<0.001). Further, elevated IL-6 was associated with death. Similarly, Ruan et al.7 identified significantly higher IL-6 levels amongst patients who die from COVID-19 compared to those who survive (11.4±8.5 pg/mL versus 6.8±3.6 pg/mL, p<0.001). **Supplementary Figure 1.** Risk of Bias Assessment via the Quality in Prognostic Studies (QUIPS) Tool of Included Cohort Studies Relating IL-6 Levels with Disease Severity



S3.

S4. SUPPLEMENTARY REFERENCES

1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in wuhan, china. *Lancet*. 2020;395(10223):497-506.

2. Diao. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19).

3. Chen L, Liu HG, Liu W, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. *Zhonghua Jie He Hu Xi Za Zhi*. 2020;43(0):E005.

4. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in wuhan, china. *Clin Infect Dis*. 2020.

5. Liu. The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. .

6. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, china. *JAMA Intern Med.* 2020.

7. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from wuhan, china. *Intensive Care Med*. 2020.